<div><p>Engineering of monoclonal antibodies (mAbs) enables us to obtain mAbs with additional functions. In particular, modifications in antibody’s Fc (fragment, crystallizable) region can provide multiple benefits such as added toxicity by drug conjugation, higher affinity to Fc receptors on immunocytes, or the addition of functional modules. However, the generation of recombinant antibodies requires multiple laborious bioengineering steps. We previously developed a technology that enables rapid <i>in vitro</i> screening and isolation of specific mAb-expressing cells from the libraries constructed with chicken B-cell line DT40 (referred to as the ‘ADLib system’). To upgrade this ADLib system with the ability to generate customized mAbs, we...
Tese de doutoramento, Farmácia (Biotecnologia Farmacêutica), Universidade de Lisboa, Faculdade de Fa...
AbstractSingle-cell based amplification of immunoglobulin variable regions is a rapid and powerful t...
Due to their low immunogenicity in patients, humanized or fully human mAbs are becoming increasingly...
Engineering of monoclonal antibodies (mAbs) enables us to obtain mAbs with additional functions. In ...
Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fas...
Monoclonal antibodies (mAb) are very important for cancer therapy, as they target cancerous cells wi...
Abstract Background Genomic, transcriptomic and proteomic projects often suffer from a lack of funct...
Cells that constitutively diversify their immunoglobulin genes can be used for selection of novel an...
Mammalian cells are the host of choice for the production of the majority of proteins with therapeut...
A rapid route for the generation of monoclonal antibodies by repertoire cloning is described. The te...
A number of recent technological developments have greatly facilitated the genetic engineering of im...
The highly specific binding characteristics of monoclonal antibodies (mAbs) have made them one of t...
Hybridomas, fusions of primary mouse B cells and myelomas, are stable, rapidly-proliferating cell li...
7noDuring the last 20 years in vitro technologies opened powerful routes to combine the generation o...
The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune e...
Tese de doutoramento, Farmácia (Biotecnologia Farmacêutica), Universidade de Lisboa, Faculdade de Fa...
AbstractSingle-cell based amplification of immunoglobulin variable regions is a rapid and powerful t...
Due to their low immunogenicity in patients, humanized or fully human mAbs are becoming increasingly...
Engineering of monoclonal antibodies (mAbs) enables us to obtain mAbs with additional functions. In ...
Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fas...
Monoclonal antibodies (mAb) are very important for cancer therapy, as they target cancerous cells wi...
Abstract Background Genomic, transcriptomic and proteomic projects often suffer from a lack of funct...
Cells that constitutively diversify their immunoglobulin genes can be used for selection of novel an...
Mammalian cells are the host of choice for the production of the majority of proteins with therapeut...
A rapid route for the generation of monoclonal antibodies by repertoire cloning is described. The te...
A number of recent technological developments have greatly facilitated the genetic engineering of im...
The highly specific binding characteristics of monoclonal antibodies (mAbs) have made them one of t...
Hybridomas, fusions of primary mouse B cells and myelomas, are stable, rapidly-proliferating cell li...
7noDuring the last 20 years in vitro technologies opened powerful routes to combine the generation o...
The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune e...
Tese de doutoramento, Farmácia (Biotecnologia Farmacêutica), Universidade de Lisboa, Faculdade de Fa...
AbstractSingle-cell based amplification of immunoglobulin variable regions is a rapid and powerful t...
Due to their low immunogenicity in patients, humanized or fully human mAbs are becoming increasingly...